Clinical Pipeline
HUMAN TRIALS IN PREPARATION
Q Therapeutics has a deep pipeline, with significant market potential backed by a strong intellectual property position.
Q Therapeutics is actively preparing for first-in-human clinical trials in transverse myelitis and amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) as an orphan drug. Trial start-up is expected in 2019.
Orphan drug designation has significant regulatory, financial and competitive advantages, including:
-
High rates of regulatory approval
-
Shorter development timelines including FDA Fast Track designation, and
-
Market exclusivity.
Existing safety and manufacturing data may also support Investigational New Drug (IND) filings for spinal cord injury and multiple sclerosis and , providing significant cost and time savings for each additional indication.
